Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders.
D014151:Anti-Anxiety Agents / Q000191:economics* / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000145:classification / Q000191:economics / Q000628:therapy*; D001315:Australia; D015928:Cognitive Behavioral Therapy / Q000191:economics*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine / Q000191:economics*; D017048:Health Care Costs; D006801:Humans; D008605:Mental Health Services / Q000145:classification / Q000191:economics*; D017059:Models, Econometric; D009010:Monte Carlo Method; D019057:Quality-Adjusted Life Years
D014151:Anti-Anxiety Agents